Hanmi Pharmaceutical Company Limited

Quick facts

Marketed products

• Amlodipine, Losartan
• Amlodipine/Losartan/Chlorthalidone · Cardiovascular
  This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis.
• Amosartan® tab · Cardiovascular
  Amosartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.
• Atorvastatin A
• Atorvastatin B
• Cavir · Other
• Cozaar® plus pro tab · Cardiovascular
  Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.
• current treatment
• one-way education
• Rosuvastatin and Ezetimibe · Cardiovascular
  Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.
• Simvast CR · Cardiovascular
  Simvastatin is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis in the liver.
• two-way education
• Victoza · Metabolic
• Zocor · Other

Phase 3 pipeline

• Amlodipine plus Losartan · Cardiovascular
  Amlodipine and losartan work together to lower blood pressure by relaxing blood vessels through calcium channel blockade and angiotensin II receptor antagonism.
• HCP0605 · Oncology
  HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP0910 · Oncology
  HCP0910 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP1004 · Oncology
  HCP1004 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP1102 · Oncology
  HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP1102Placebo+HGP0711 · Endocrinology / Diabetes
  HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry.
• HCP1105 · Oncology
  HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP1202 · Diabetes
  HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
• HCP1302 · Diabetes
  HCP1302 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HCP1401 · Endocrinology
  HCP1401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HCP1701 · Endocrinology / Diabetes
  HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HCP1803-3 · Diabetes
  HCP1803-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• HCP1903
• HCP1904-1 · Oncology
  HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HCP1904-2 · Diabetes
  HCP1904-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HCP1904-3 · Diabetes
  HCP1904-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HCP2102-1 · Endocrinology / Metabolic Disease
  HCP2102-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• HCP2102-2 · Diabetes
  HCP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• HGP0412 capsule · Oncology
  HGP0412 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• HGP0608 · Musculoskeletal / Endocrinology
  HGP0608 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.
• HGP0816 · Oncology
  HGP0816 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
• HGP0904 · Oncology
  HGP0904 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• HGP1011 · Endocrinology
  HGP1011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1201 · Endocrinology / Diabetes
  HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1408 · Oncology
  HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression.
• HGP1705 · Diabetes
  HGP1705 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1805 · Diabetes
  HGP1805 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1909 · Diabetes
  HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1910 · Endocrinology
  HGP1910 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP1911 · Endocrinology
  HGP1911 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HGP2102-1 · Diabetes
  HGP2102-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HGP2102-2 · Endocrinology / Diabetes
  HGP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HIP0612 · Oncology
  HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• HIP1402 · Diabetes
  HIP1402 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HIP1601 · Endocrinology / Diabetes
  HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• HIP2101 · Oncology
  HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects.
• HM11260C · Oncology
  HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• HPP2002-1 · Diabetes
  HPP2002-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• HPP2003-3 · Diabetes
  HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HPP2004 · Diabetes
  HPP2004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

Phase 2 pipeline

• Amosartan Plus Tab.
• Amosartan Q tablet
• Esomezol Cap
• Hanmi Tams® Capsule
• HCP1803
• HM10560A
• HM15136
• HM15211 · Oncology
  HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.
• HM15275
• HM15912 Active
• HPP2005
• RLD2003
• RLD2004
• RLD2005

Phase 1 pipeline

• Ambroxol and Levodropropizine
• amosartan and rosuvastatin
• BH3120
• HCP0816
• HCP0918
• HCP1007
• HCP1201, Fasted followed by fed
• HCP1201, Fed followed by fasted
• HCP1303
• HCP1305
• HCP1306
• HCP1704
• HCP1801
• HCP1805
• HCP1902
• HCP2001
• HCP2201
• HCP2202
• HCP2303
• HGP0904 and HGP1201 co-administraion
• HGP0918
• HGP0919
• HGP1103
• HGP1206
• HGP1404
• HGP1405
• HGP1406
• HGP1501
• HGP1602
• HGP1607
• HGP1809
• HGP1810
• HGP1812
• HGP2001
• HIP0908
• HIP1302
• HIP1403
• HIP1503
• HIP1601 40mg
• HIP1701

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hanmi Pharmaceutical Company Limited portfolio CI brief
• Hanmi Pharmaceutical Company Limited pipeline updates RSS